Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vetter Receives “Known Consignor” Approval from Germany's Federal Aviation Office

Published: Wednesday, December 12, 2012
Last Updated: Wednesday, December 12, 2012
Bookmark and Share
The CDMO meets new requirements six months ahead of deadline.

Vetter has announced that it has now been approved as a “Known Consignor” by the German Federal Aviation Office. The agency officially granted the pharmaceutical service provider the certificate of approval following an audit at Vetter´s Holbeinstrasse and Ravensburg Vetter West facilities.

The approval means that customers will continue to have their air cargo products loaded, transported and delivered quickly and safely, saving valuable time and money.

Vetter had already been designated as a “Known Consignor” back in 2006. The goal of the certification is primarily to provide more security for air cargo.

Until recently, logistics companies themselves issued the certificate. New EU regulations concerning the so-called "safe supply chains" require that companies must now have their status audited and approved by the Federal Aviation Office.

The criteria for certification are extensive and include elaborating a safety concept, training personnel, and the assurance that the shipping of freight is performed in a way that cannot be tampered with.

Any attempt to open the shipment would be immediately evident. The Federal Aviation Office grants the certificate for five years and carries out unannounced controls on a regular basis.

"Our approval as a "Known Consignor" allows our customers fast and smooth loading of air freight packages at the airport, including a high level of security,” said managing director Thomas Otto.

Otto continued, “Once time-consuming x-rays and searches are no longer necessary, saving invaluable effort and cost. For Vetter, the status of ”Known Consignor” is further proof of the high product quality that we offer our customers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vetter Announces Completion of its Schuetzenstrasse Multi-Functional Building
2015 developments reflect another positive year of growth for the pharmaceutical service provider.
Sunday, January 31, 2016
Vetter Receives Internationally Recognized AEO-F Certificate
Pharmaceutical service providers and customers benefit from comprehensive tariff advantages.
Wednesday, December 02, 2015
Vetter Announces Office Opening in Japan
Company’s second office in the region will strengthen customer relations and help develop new business among emerging and established Japanese companies.
Thursday, October 15, 2015
Vetter Embarks on a 300 Million Euro Investment Strategy
Company will invest for further development to its manufacturing sites and to make available additional manufacturing capacities.
Thursday, October 01, 2015
Vetter Development Service Chicago Completes Recent On-Site Expansion Activities
Continued demand and increased customer product transfers are generating a positive business outlook for the company’s early-stage development facility.
Thursday, June 11, 2015
Vetter Serializes the First Product for South Korea
CDMO produces clearly identifiable labelling for a top-ten pharmaceutical company.
Saturday, May 02, 2015
Vetter Appoints Oliver Albrecht as Managing Director
Role with company commenced on April 1, 2015.
Thursday, April 09, 2015
Vetter Continues to Expand Capacity
Structural work completed on Vetter’s new multi-functional building for its Development Service and information technology (IT).
Friday, January 30, 2015
Vetter Adds Flexible Serialization Service to its Portfolio
A new service allowing for the explicit identification of drug packaging.
Thursday, December 04, 2014
Vetter Announces Opening of Office to Support Growing Asian Healthcare Market
New Asia Pacific office will support customer relations and the development of new business.
Friday, November 21, 2014
Vetter Announces Personnel Changes in its Development Service Division
Clinical manufacturing services continue to attract new business.
Saturday, October 18, 2014
Vetter Continues to Strengthen its Market Position
Another positive year for the CDMO.
Wednesday, January 15, 2014
Vetter to Construct New Filling Lines to Expand Capacity
Responding to customer demand and company growth.
Thursday, October 10, 2013
Vetter’s Newest Facility Successfully Completes FDA Inspection
Center for visual inspection and logistics sets high safety and control standards.
Thursday, March 28, 2013
Vetter Receives Top Prize at the European Outsourcing Awards Ceremony
CDMO clinches an industry Oscar for its innovative high-speed filling line.
Friday, October 12, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!